2022 World Conference on Lung Cancer (ePosters)-EP08.02-168. Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute

EP08.02-168. Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute

Back to course

Pdf Summary

This study aimed to analyze the efficacy, safety, and treatment courses of ALK-TKIs (anaplastic lymphoma kinase tyrosine kinase inhibitors) in patients with ALK-positive non-small cell lung cancer (NSCLC). The researchers retrospectively analyzed data from 26 patients who started first-line treatment with ALK-TKIs after January 2012 at a single medical center in Osaka, Japan. The patients' characteristics included a median age of 56, 20 non-smokers and 6 smokers, 2 with a history of other malignancy, 25 with adenocarcinoma histology and 1 with large cell histology, and an equal distribution of female and male patients. The majority of patients had an ECOG-PS score of 1, and 7 had brain metastasis at the start of treatment. The study showed that alectinib was the most commonly used ALK-TKI, with 30 patients receiving it. In terms of adverse events, one patient experienced ILD (interstitial lung disease) with crizotinib, one had increased creatinine with ceritinib, and six experienced various side effects with lorlatinib. Overall survival data showed a median overall survival of 61.4 months, but the data for brain metastasis did not significantly affect overall survival. The study also mentioned that third-generation ALK-TKIs have shown meaningful responses for patients who are refractory to earlier generations, but their adverse events can be problematic. In conclusion, the study demonstrated that ALK-TKIs can provide preferable outcomes for patients with ALK-positive NSCLC, including those with brain metastasis, and highlighted the need for further research on sequencing treatment strategies using ALK-TKIs.

Asset Subtitle

Yuki Akazawa

Meta Tag

Speaker Yuki Akazawa

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ALK-TKIs

efficacy

safety

NSCLC

retrospective analysis

adverse events

overall survival

brain metastasis

alectinib

sequencing treatment strategies